Global Rapid Acting Insulin Market to Reach USD 11.3 Billion by 2033, Impelled by Rising Diabetic Population

December 19, 2024 | Healthcare

According to the latest report by IMARC Group, titled "Rapid Acting Insulin Market Report by Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2025-2033" the global rapid acting insulin market reached a value of USD 8.0 Billion in 2024. Rapid acting insulin refers to a device that is generally used for controlling glucose levels in patients suffering from diabetes. It can either be delivered via insulin pumps or administered into the bloodstream with a syringe. Apart from this, it can also be inhaled through the mouth. There has been a considerable increase in the adoption of rapid acting insulins across the globe due to the increasing awareness among the masses and the easy product availability via online and offline pharmacy retail channels.

Global Rapid Acting Insulin Market Trends:

The global market is primarily driven by the rising prevalence of diabetes among individuals. This is supported by the rising consumption of fast foods and the sedentary lifestyle led by the majority of the masses. Coupled with the increasing risks of severity and mortality among patients suffering from other chronic illnesses, this is creating a positive outlook for the market. Additionally, continuous product innovations, such as the introduction of advanced rapid acting insulins with improved glycemic control, are gaining widespread prominence among individuals and healthcare professionals. Along with this, rising investments by public and private firms for upgrading the existing healthcare infrastructure is propelling the market growth. Furthermore, numerous initiatives undertaken by the governments of multiple countries to create awareness regarding the adverse effects of diabetes, along with the importance of effective treatments, are positively influencing the market growth. Other factors, including the increasing healthcare expenditure and extensive research and development (R&D) activities conducted by key players, are also contributing to the market growth. On account of the aforementioned factors, the market is anticipated to reach a value of USD 11.3 Billion by 2033, growing at a CAGR of 3.9% during 2025-2033.

Market Summary:

  • On the basis of the product, the market has been segmented into lispro, aspart and glulisine insulins.
  • Based on the indication, the market has been bifurcated into type 1 and type 2 diabetes.
  • On the basis of the distribution channel, the market has been segregated into hospital pharmacies, drug stores and retail pharmacies and online stores.
  • Based on the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players are Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.


Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Product, Indication, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA - Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Rapid Acting Insulin Market to Reach USD 11.3 Billion by 2033, Impelled by Rising Diabetic Population
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials